Trial Profile
A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Pelareorep (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Oncolytics Biotech
- 02 Apr 2020 Results presented in an Oncolytics Media Release.
- 02 Apr 2020 According to an Oncolytics Biotech media release, data were published by Dr. Sanjay Goel, Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, et al., was published on March 10, 2020, in Molecular Cancer Therapeutics.
- 17 Dec 2018 Status changed from active, no longer recruiting to completed.